In this article, the author focuses on the ongoing genomic research along with genetic variants associated with urinary bladder cancer risk. Topics discussed include advancement in medication including the possibility of indentifying the single-nucleotide polymorphism (SNP) interactions; risks associated with bladder cancer; and impact of genetic variants on prognosis.